HomeAll New Products Listed Chronologically

All New Products Listed Chronologically

Catalog No. Product Name Information Isotype
E4908 Clemizole hydrochloride Clemizole hydrochloride is an H1 histamine receptor antagonist, is found to substantially inhibit HCV replication. Clemizole hydrochloride is an inhibitor of TRPC5 channel. The IC50 of Clemizole hydrochloride for RNA binding by NS4B is 24 nM, whereas its EC50 for viral replication is 8 μM. Dec 19 2024
E7009 D-Glucose-13C6 D-Glucose-13C6 is a stable isotope-labeled counterpart of D-glucose (HY-B0389). D-Glucose-13C6 can be used as a metabolic tracer to trace glucose-related synthetic catabolism or as synthesis ingredient, minimal media reagent, and internal standard. Dec 19 2024
E7212 7-Desmethyl-agomelatine 7-Desmethyl-agomelatine is a metabolite of Agomelatine. Agomelatineis a potent agonist at melatonin receptors (MT1 and MT2), and also is an antagonist of 5-HT2C. Dec 19 2024
E7434 Illudin S Illudin S, a cytotoxic Illudin, is a natural sesquiterpene with strong anti-tumour and antiviral activities. Illudin S has genotoxic activities. Illudin S blocks the G1-S phase interface of the cell cycle in human leukemia cells. Dec 19 2024
S7468 SR 11302 SR 11302 is an activator protein-1 (AP-1) transcription factor inhibitor. SR 11302 is a retinoid that specifically inhibits AP-1 activity without activating the transcription of retinoic acid response element (RARE). Dec 19 2024
E7213 TAPI-1 TAPI-1 is a TACE (ADAM17) inhibitor and blocks the shedding of several cell surface proteins. TAPI-1 is also a metalloproteinase (MMP) inhibitor. Dec 19 2024
E7435 Galactose Oxidase, Dactylium dendroides Galactose Oxidase, Dactylium dendroides (GOase) from fungus is often used in biochemical studies. Galactose oxidase is a type II copper metalloenzyme, and it containing a single polypeptide. Galactose oxidase catalyzes two-electron oxidation of primary alcohols to their corresponding aldehydes, coupling with the reduction of dioxygen to hydrogen peroxide. Dec 19 2024
E4737 Potrasertib Potrasertib (IMP7068, WEE1-IN-10) is a potent and selective inhibitor of WEE1 Kinase. It displays antitumor activity and is well-tolerated in patients with advanced solid tumors. Dec 18 2024
S8593 VX-984 VX-984 (M9831) is an orally active, potent, selective, and ATP-competitive inhibitor of DNA-PK. VX-984 effectively suppresses non-homologous end joining (NHEJ) and increases DNA double-strand breaks (DSBs). It enhances the cytotoxic effects of ionizing radiation (IR) in various cancer cell lines, including non-small cell lung cancer (NSCLC) cell lines, in vitro. Additionally, VX-984 reduces DNA-PKcs autophosphorylation. Dec 18 2024
E1462 P62-mediated mitophagy inducer P62-mediated mitophagy inducer (PMI) is a P62-mediated activator of mitophagy that functions independently of parkin recruitment or mitochondrial membrane potential (ΔΨm) collapse. It remains effective even in cells lacking a fully functional PINK1/Parkin pathway. PMI stabilizes Nrf2 and enhances p62 expression, thereby activating mitophagy. Dec 18 2024
E6024 Selumetinib sulfate Selumetinib sulfate (AZD6244 sulfate, ARRY-142886 sulfate) is an oral, non-ATP-competitive inhibitor of MEK1/2, with an IC50 of 14 nmol/L against purified MEK1. It exhibits an anti-tumor effect in the HT-29 xenograft model and is used to treat cancer and inflammation. Dec 18 2024
E4781 OPN expression inhibitor 1 Dec 16 2024
E1974 MS8709 MS8709 (EX-A11295) is a first-in-class G9a/GLP proteolysis targeting chimera (PROTAC) degrader, that induces G9a/GLP degradation in a concentration, time, and ubiquitin-proteasome system (UPS)-dependent manner, and does not alter the mRNA expression of G9a/GLP over other methyltransferases. It displays superior cell growth inhibition in prostate, leukemia, and lung cancer cells over parent G9a/GLP inhibitors. Dec 16 2024
E4771 Aprocitentan Aprocitentan (ACT-132577) is a pharmacologically active metabolite of Macitentan. Aprocitentan is an orally active dual antagonist of ETA/ETB with IC50 values of 3.4 nM and 987 nM, and pA2 values of 6.7 and 5.5, respectively. Dec 16 2024
E1984 JBJ-09-063 hydrochloride JBJ-09-063 hydrochloride is a mutant-selective allosteric inhibitor of EGFR with IC50 values of 0.147 nM, 0.063 nM, 0.083 nM and 0.396 nM for EGFR L858R, EGFR L858R/T790M, EGFR L858R/T790M/C797S and EGFRLT/L747S, respectively. JBJ-09-063 hydrochloride significantly inhibits the phosphorylation of EGFR, Akt, and ERK1/2. Dec 16 2024
E1863 Inixaciclib Inixaciclib (NUV-422) is a potent inhibitor of CDK2, CDK4, and CDK6. It inhibits the growth of glioma cell lines in vitro and exhibits antitumor activity in GB xenograft models, PDX models of HR+ HER2- metastatic breast cancer resistant to CDK4/6 inhibitors and prostate cancer resistant to anti-androgens. Dec 12 2024
E1941 ACT-1016-0707 ACT-1016-0707 (LPA1 receptor antagonist 2) is an orally active and selective antagonist of LPA1 Receptor, with IC50 of 3.1 nM for hLPAR1 in tango assay. It has the potential to treat fibrotic diseases. Dec 12 2024
E4738 LYMTAC-2 LYMTAC-2 is a lysosomal-targeting chimera (LYMTAC) designed to degrade membrane-associated proteins by leveraging lysosomal membrane proteins (LMPs) like RNF152, LAPTM4a, and LAPTM5. It forms a ternary complex with its target protein, such as KRASG12D, and facilitates relocalization to the lysosome, leading to ubiquitin-dependent degradation. It has the potential to study membrane protein regulation and develop strategies to overcome resistance in KRAS-driven signaling pathways. Dec 12 2024
E4612 iCARM1 iCARM1 (CARM1-IN-6) is a potent and selective inhibitor of protein arginine methyltransferase CARM1 (PRMT4) with an IC50 of 12.3 μM. It potently suppresses breast cancer cell growth both in vitro and in vivo and can be used in cancer research. Dec 12 2024
E6011 Agomelatine hydrochloride Agomelatine hydrochloride (S-20098 hydrochloride) is a specific agonist of MT1 and MT2 receptors with Kis of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively. It is also a selective antagonist of 5-HT2C receptors with pKis of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively. Blockade of these receptors enhances adrenergic and dopaminergic transmission in the frontocortical regions. Dec 12 2024